Drug intelligence / Profile preview

ZKLJ02

Development stage: Phase 1
Lead developer: Kunming Longjin Pharmaceutical
Modality: Small Molecules
Administration: Intravenous

Overview

ZKLJ02 is an innovative small molecule chemical drug developed by Yunnan Zhongke Longjin Biological Technology for the treatment of acute ischemic stroke (AIS). It is designed as a neuroprotective agent to mitigate brain damage and improve neurological function recovery following an ischemic event. The drug is currently in Phase I clinical development in China, with studies focusing on the safety, tolerability, and pharmacokinetics of the injectable formulation in healthy volunteers. ZKLJ02 is classified as a Class 1 innovative drug in the Chinese regulatory framework.

Beyond the preview

Go deeper on ZKLJ02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZKLJ02.

Explore the full profile